SkinHealth Systems Inc. reports developments tied to its global medical aesthetics business, with recurring updates on financial results, margin performance, adjusted EBITDA, installed-base activity and its recurring consumables model. The company, formerly The Beauty Health Company, trades on the Nasdaq Capital Market under the symbol SKIN.
Company news also covers the Hydrafacial platform, SkinStylus microneedling and nano-channeling treatments, HydraScalp with Keravive, provider adoption, consumer skin-health research, board appointments and the completed corporate rebrand to SkinHealth Systems.
SkinHealth Systems (SKIN) will report third quarter 2026 financial results after market close on November 5, 2026. An investor conference call will follow at 4:30 p.m. Eastern Time. The webcast and supporting materials will be available on the company’s investor relations website, with a recording available approximately three hours after the call concludes.
SkinHealth Systems (Nasdaq: SKIN) will implement a 1-for-20 reverse stock split of its Class A common stock on October 14, 2026.
The split takes effect at 12:00 a.m. ET, with split-adjusted trading expected at market open that day. The company intends the split to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement. Based on shares outstanding as of October 7, 2026, the outstanding count is expected to fall from approximately 130.3 million to 6.5 million. Authorized shares will remain unchanged. The conversion rate of its 7.95% Convertible Senior Secured Notes due 2028 will be adjusted proportionately.
SkinHealth Systems (SKIN) launched the HydraClear Treatment Booster through its Hydrafacial brand to address the appearance of blemish-prone skin. The booster combines salicylic, succinic and tranexamic acids in an alcohol-free formula. It is delivered through Deluxe and Platinum Hydrafacial treatments and can be paired with blue LED light therapy.
A 12-week study involving 26 participants with mild-to-moderate acne evaluated a treatment program incorporating Hydrafacial treatments and HydraClear. At Week 12, four weeks after the fourth treatment, investigator assessments found a 38% mean reduction in total blemishes versus baseline; 81% of participants showed fewer visible blemishes. These findings concern the treatment program, rather than the booster used alone. Individual results may vary.
SkinHealth Systems (SKIN) has expanded its SkinStylus SteriLock MicroSystem into Europe, making the professional skin-treatment device available in six countries.
The microneedling and nano-needling device, intended for cosmetic use, is now available in the UK, Ireland, Germany, France, Spain and Portugal. It will be sold through the company’s direct European commercial organization, using Hydrafacial’s established provider relationships. SkinHealth Systems acquired SkinStylus in 2023 to broaden its professional skin health portfolio beyond Hydrafacial treatments.
SkinHealth Systems (SKIN) will present new clinical data for its Hydrafacial™ and HydraScalp™ with Keravive™ treatments at the Science of Skin Summit in Austin, Texas, on September 17-20, 2026.
A randomized, evaluator-blinded study of a single HydraScalp treatment showed significantly improved scalp hydration, reduced dryness and visible adherent dandruff, enhanced scalp smoothness, and maintenance of epidermal barrier integrity, supporting an optimized scalp microenvironment for long-term scalp and hair health. A Phase IV open-label study of monthly Deluxe Hydrafacial treatments with the ReGen GF™ Booster across Fitzpatrick skin types I–VI found that 100% of subjects had Global Aesthetic Improvement, with statistically significant gains in skin hydration and quality, including skin roughness, wrinkles, elasticity, and pore size.
The e-posters will be available on touchscreen monitors and in the summit mobile app.
SkinHealth Systems (SKIN) launched two Hydrafacial Treatment Enhancers, HydraGlow Pre-Extraction Peel and Hydralock HA Biocellulose Mask, to deepen treatment personalization and elevate results.
HydraGlow Pre-Extraction Peel is applied before the Hydrafacial peel and extraction step to help loosen dirt, oil, and pore-clogging impurities. It combines exfoliating acids, glycerin, and a hyaluronic acid complex to refine texture and support skin hydration. In a split-face study of 23 participants across all Fitzpatrick skin types, it helped improve exfoliation by nearly two times, with providers reporting easier, more effective extractions and 100% of participants noting healthier, more radiant-looking skin and clearer-looking pores.
Hydralock HA Biocellulose Mask hydrates, soothes, and replenishes the skin barrier, providing a cooling sensation that pairs well with LED light therapy. Both enhancers can be used separately or together and are now available to Hydrafacial providers in the U.S.
SkinHealth Systems (NASDAQ: SKIN), home to Hydrafacial, launched Hydrafacial Impact, a national provider education program aimed at helping aesthetic practices maximize their Hydrafacial investment and support sustainable, profitable growth. The inaugural series will visit nine U.S. markets through the end of 2026, including New York and Long Beach.
Hydrafacial Impact focuses on operational drivers of practice performance, covering membership program best practices, combination treatment protocols, personalization techniques and ROI-focused strategies. It extends SkinHealth Systems’ broader education platform, which has trained more than 60,000 providers worldwide through certifications, dinner series, in-office trainings, webinars and over 120 on-demand programs.
SkinHealth Systems (NASDAQ: SKIN) reported Q2 2026 net sales of $72.1 million, down 7.8% year over year, as both delivery systems and consumables declined. The company placed 770 delivery systems versus 957 a year ago, while the active install base increased to 36,516.
GAAP gross margin rose to 68.4% from 62.8%, and adjusted gross margin to 71.8%. Operating expenses fell to $45.8 million, supporting adjusted EBITDA of $17.0 million (23.6% margin), up from $13.9 million. Net loss was $(2.7) million versus prior net income of $19.7 million, mainly reflecting a prior-year $18.1 million gain on 2026 notes.
For Q3 2026, the company guides net sales of $65–$70 million and adjusted EBITDA of $5–$7 million. For full-year 2026, it forecasts net sales of $280–$290 million and adjusted EBITDA of $39–$46 million, assuming stable market conditions and ongoing cost discipline.
SkinHealth Systems (NASDAQ: SKIN) will release its second quarter 2026 financial results after market close on Thursday, August 6, 2026, followed by an investor conference call at 4:30 p.m. Eastern Time. A live webcast, supporting materials, and a replay will be available on the company’s investor relations website.
SkinHealth Systems (NASDAQ: SKIN) received new FDA clearance for the SkinStylus SteriLock MicroSystem to improve the appearance of periorbital wrinkles in adults 22+ across all Fitzpatrick skin types.
SkinStylus is now the only microneedling device with FDA-cleared indications for facial acne scars, periorbital wrinkles, and abdominal hypertrophic scars, supporting its role alongside Hydrafacial treatments in a rapidly growing U.S. microneedling market estimated at $330 million in 2025.